What was the revenue generated by MiSight in the U.S. in the first quarter of 2021 
h back-to-school activity being in person. But that's on the come, and I hope that happens.
We're not really counting on that or trying to build that into our guidance. But we are seeing new fits continue to improve. Demand is there. We're seeing that on a global basis.
I don't want to get into quarters or months. But I mean, I will say February grew. So, CooperVision grew in February, which was another good positive step in the right direction.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
That's super helpful. And Al, on MiSight, any color on China, the likelihood of China getting approval in 2021? And on Essilor, how do you see this playing out long term? You guys both have other myopia management products. Can you -- I know it's early, but can you envision kind of this JV building becoming broader over time with, in addition to SightGlass?
Al White -- President and Chief Executive Officer
Sure. Yeah. With respect to China, we're continuing to have conversations on the regulatory front there. We'll see.
Not too much to update on that. I mean, still, I would kind of say cautious optimism that we get approval at some point here this year but still some decent work to do on that. With respect to Essilor and the JV, yeah, I mean, Essilor is a great company. We have a great relationship with those guys.
We're starting that myopia management journey together, if you will. They have a spectacle in the market. We obviously have a lot of products in the market between Ortho-k and MiSight. Coming together on SightGlass Vision should be a home run.
We're all alike mindset of wanting to be really successful there. Ultimately, does that JV expand and include other things, potentially, we'll see how that plays out. I mean, right now, there's so much activity, and we're having so much success that we have our hands full, certainly. But if it makes sense, if it makes strategic sense, it's something we would evaluate certainly.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Thanks, Al.
Operator
Next is Matthew O'Brien from Piper Sandler. Your line is now open.
Matthew O'Brien -- Piper Sandler -- Analyst
Thanks. Afternoon. Thanks for taking my questions. Al, I hate to talk about a product that's 0.5% of sales this quarter, but MiSight gets a ton of attention.
So, can you bridge us from this 3 to 25 million this year just because it's all going to be domestic, right? I mean international is probably not going to contribute a ton of a big. I'm sure Russia will be nice, but it's going to primarily be domestic. You've got 3,000 people here that are trained. If you do the math, it's like they need to basically put a patient on per month for the last nine months of this year.
So, can you just give us some more color, it really bridges to the -- from 3 million up to 25 million for the full year to make us comfortable that you can get there?
Al White -- President and Chief Executive Officer
Sure. I mean, first of all, I would say that our growth outside of the U.S. was 80% or so. So, I mean, you're talking about -- the vast majority of that 3 million in sales was outside of the U.S., growing somewhere in the 80-plus percent kind of range.
We're getting good growth here in the Americas when you look at somewhere like Canada. We're just at the very early stages here in the U.S. of a lot of the revenue recognition. So, we have thousands of kids, a couple of thousands or more wearing the lens right now.
So, I think if we continue to be successful here in the U.S., that's great, and we will continue to be successful. I mean, I see the numbers; I see the ramps coming, I see the fittings all the way through February here, see the revenues moving up nicely, all that kind of stuff. But I would not diminish outside of the U.S. I mean, whatever, it was 2.9 million, growing 80% and accelerating.
So, that's going to drive a lot of the growth.
Matthew O'Brien -- Piper Sandler -- Analyst
Yeah. And sorry, just to be more clear, I think last quarter, it was 2.5 million. And then, this quarter, it was 3 million. And I think you said you just did 10
h back-to-school activity being in person. But that's on the come, and I hope that happens.
We're not really counting on that or trying to build that into our guidance. But we are seeing new fits continue to improve. Demand is there. We're seeing that on a global basis.
I don't want to get into quarters or months. But I mean, I will say February grew. So, CooperVision grew in February, which was another good positive step in the right direction.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
That's super helpful. And Al, on MiSight, any color on China, the likelihood of China getting approval in 2021? And on Essilor, how do you see this playing out long term? You guys both have other myopia management products. Can you -- I know it's early, but can you envision kind of this JV building becoming broader over time with, in addition to SightGlass?
Al White -- President and Chief Executive Officer
Sure. Yeah. With respect to China, we're continuing to have conversations on the regulatory front there. We'll see.
Not too much to update on that. I mean, still, I would kind of say cautious optimism that we get approval at some point here this year but still some decent work to do on that. With respect to Essilor and the JV, yeah, I mean, Essilor is a great company. We have a great relationship with those guys.
We're starting that myopia management journey together, if you will. They have a spectacle in the market. We obviously have a lot of products in the market between Ortho-k and MiSight. Coming together on SightGlass Vision should be a home run.
We're all alike mindset of wanting to be really successful there. Ultimately, does that JV expand and include other things, potentially, we'll see how that plays out. I mean, right now, there's so much activity, and we're having so much success that we have our hands full, certainly. But if it makes sense, if it makes strategic sense, it's something we would evaluate certainly.
Larry Biegelsen -- Wells Fargo Securities -- Analyst
Thanks, Al.
Operator
Next is Matthew O'Brien from Piper Sandler. Your line is now open.
Matthew O'Brien -- Piper Sandler -- Analyst
 Thanks. Afternoon. Thanks for taking my questions. Al, I hate to talk about a product that's 0.5% of sales this quarter, but MiSight gets a ton of attention.
So, can you bridge us from this 3 to 25 million this year just because it's all going to be domestic, right? I mean international is probably not going to contribute a ton of a big. I'm sure Russia will be nice, but it's going to primarily be domestic. You've got 3,000 people here that are trained. If you do the math, it's like they need to basically put a patient on per month for the last nine months of this year.
So, can you just give us some more color, it really bridges to the -- from 3 million up to 25 million for the full year to make us comfortable that you can get there?
Al White -- President and Chief Executive Officer
Sure. I mean, first of all, I would say that our growth outside of the U.S. was 80% or so. So, I mean, you're talking about -- the vast majority of that 3 million in sales was outside of the U.S., growing somewhere in the 80-plus percent kind of range.
We're getting good growth here in the Americas when you look at somewhere like Canada. We're just at the very early stages here in the U.S. of a lot of the revenue recognition. So, we have thousands of kids, a couple of thousands or more wearing the lens right now.
So, I think if we continue to be successful here in the U.S., that's great, and we will continue to be successful. I mean, I see the numbers; I see the ramps coming, I see the fittings all the way through February here, see the revenues moving up nicely, all that kind of stuff. But I would not diminish outside of the U.S. I mean, whatever, it was 2.9 million, growing 80% and accelerating.
So, that's going to drive a lot of the growth.
Matthew O'Brien -- Piper Sandler -- Analyst
Yeah. And sorry, just to be more clear, I think last quarter, it was 2.5 million. And then, this quarter, it was 3 million. And I think you said you just did 10